Groundbreaking immunomodulation – towards safer and more targeted treatments for autoimmune diseases

Important results from the project

The project has largely met its objectives. Serendo has been able to confirm that previously identified EA2 inhibitors bind to the target protein Endophilin A2 in orthogonal assays, which is an important validation for continued preclinical development. The project has also strengthened dialogues with investors and pharmaceutical companies and contributed to external validation, including the Abbvie Golden Ticket award.

Expected long term effects

In the longer term, the project may contribute to the development of a new class of more selective immunomodulatory drugs for autoimmune diseases. The results reduce the early development risk and strengthen the possibility of attracting capital, strategic partnerships and continued project funding. If continued validation confirms the effect in human systems, the technology may contribute to safer and more accurate treatments for patients.

Approach and implementation

The project was carried out in collaboration with established contract organizations and external experts. The work included production of EA2 protein, biochemical binding validation of small molecule inhibitors and initiation of functional studies in human systems. Serendo was responsible for project management, scientific analysis and prioritization of candidates, while specialized partners contributed infrastructure and analytical capacity.